COMMUNIQUÉS West-GlobeNewswire

Actelion provides an update on the Phase III IMPACT program with cadazolid in CDAD
08/06/2017
ALLSCHWIL, SWITZERLAND - 08 June 2017 - Actelion Ltd (SIX: ATLN) today provided an update on the Phase III program IMPACT to investigate the efficacy and safety of Actelion's novel anti-infective cadazolid versus [...]
Bone Therapeutics SA : completes patient recruitment for pivotal interim analysis of Phase III Osteonecrosis trial with PREOB®
08/06/2017
Regulated information Bone Therapeutics completes patient recruitment for pivotal interim analysis of Phase III Osteonecrosis trial with PREOB ® Positive results could lead to further validation of Company's bone-cell [...]
Bone Therapeutics SA : finalise le recrutement des patients pour l'analyse intermédiaire de l'étude de Phase III avec PREOB® dans l'ostéonécrose
08/06/2017
Information réglementée Bone Therapeutics finalise le recrutement des patients pour l'analyse intermédiaire de l'étude de Phase III avec PREOB ® dans l'ostéonécrose Des résultats positifs permettraient de poursuivre la [...]
VALNEVA : Déclaration d'actions et de droits de vote - Mai 2017
07/06/2017
VALNEVA Déclaration d'actions et de droits de vote - MAI 2017 Dénomination sociale : VALNEVA Adresse du siège social : World Trade Center Lyon, Tour Oxygène, 10-12 Boulevard Marius Vivier Merle, 69003 Lyon Marché [...]
Novartis interim results from global, pivotal CTL019 trial show durable complete responses in adults with r/r DLBCL
07/06/2017
At interim analysis, three-month overall response rate (ORR) was 45%, with 37% complete response (CR); all patients in CR at three months remained in CR at data cutoff Best ORR was 59%, with 43% achieving CR; full [...]
Medtronic Initiates U.S. Launch of World's First Hybrid Closed Loop System for Type 1 Diabetes
07/06/2017
The MiniMed(TM) 670G System Features the Company's Most Advanced SmartGuard(TM)HCL Technology and New Guardian(TM) Sensor 3 DUBLIN - June 7, 2017 - Medtronic plc (NYSE:MDT), today announced the U.S. launch of the [...]
Oxford BioMedica plc: Oxford BioMedica notes FDA Advisory Committee to review CTL019
07/06/2017
Oxford BioMedica notes FDA Advisory Committee to review CTL019 London, UK - 7 June 2017: Oxford BioMedica plc ("Oxford BioMedica" or "the Group") (LSE:OXB), a leading gene and cell therapy group, notes that the US Food [...]
Around the World in 365 Days - Taping the World for Health
07/06/2017
ALBUQUERQUE, N.M., June 07, 2017 (GLOBE NEWSWIRE) -- The Father of elastic, therapeutic taping and the genius of the Kinesio Taping® Method, Dr. Kenzo Kase looks to educate the world on the health benefits from Kinesio [...]
ObsEva SA Announces the Completion of a Phase 1 PK/PD Clinical Trial Evaluating Different Doses of OBE2109 and Add-Back Therapy
07/06/2017
- OBE2109 is a GnRH receptor antagonist currently in development as both a stand-alone treatment and with add-back therapy designed to address the needs of endometriosis and uterine fibroid patients - Geneva, [...]
Midatech signs global license agreement to investigate panobinostat for treatment of brain cancers
07/06/2017
7 June 2017 Midatech Pharma PLC ("Midatech", "Company" or "Group") Midatech signs global license agreement to investigate panobinostat for treatment of brain cancers Midatech Pharma (AIM: MTPH; Nasdaq: MTP), the [...]
Biocartis Group NV: MRC Technology and Biocartis initiate development of liquid biopsy test for breast cancer
07/06/2017
PRESS RELEASE: 7 June 2017, 07:00 CEST MRC Technology and Biocartis initiate development of liquid biopsy test for breast cancer Partnership aimed at the development of molecular diagnostic assays on Biocartis' fully [...]
Solon Eiendom ASA - Primary insider notification
06/06/2017
SOLON EIENDOM ASA STOCK EXCHANGE ANNOUNCEMENT Solon Eiendom ASA - Primary insider notification (Oslo, Norway, 6 June 2017) Solon Eiendom ASA Chairman of the Board Simen Thorsen (through his wholly owned company Hortulan [...]
ProMIS(TM) Neurosciences Appoints William C. Mobley to Scientific Advisory Board
06/06/2017
TORONTO and CAMBRIDGE, Mass., June 06, 2017 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX:PMN), a biotechnology company focused on the discovery and development of precision treatments for neurodegenerative [...]
Essilor : Nombre total de droits de vote et d'actions composant le capital social au 31 mai 2017
06/06/2017
Nombre total de droits de vote et d'actions composant le capital social au 31 mai 2017 (Article L.233-8 II du Code de Commerce et les articles 221-1 et 223-16 du Règlement Général de l'AMF) Charenton-le-Pont, France (le [...]
Essilor: Disclosure of Share Capital and Voting Rights Outstanding as of May 31, 2017
06/06/2017
Disclosure of Share Capital and Voting Rights Outstanding as of May 31, 2017 (Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des [...]
Ossur Hf : Transactions in relation to share buyback program
06/06/2017
Announcement from Össur hf. No. 43/2017 Reykjavík, 05 June 2017 On 1 December 2016, Össur hf. initiated a new share buy-back program, see Company announcement no. 96/2016. The purpose of the share buyback program is to [...]
Issuance of new shares to the Finnish Innovation Fund Sitra pursuant to the financing arrangement announced on 21 July 2016
06/06/2017
Company announcement, Helsinki, 6 June 2017 at 7:00 pm Nexstim Plc (NXTMH:HEX, NXTMS:STO) (" Nexstim " or " Company "), a medical technology company developing and marketing pioneering navigated non-invasive brain [...]
MITHRA SIGNS EXCLUSIVE AGREEMENT FOR TIBELIA® IN CANADA
06/06/2017
PRESS RELEASE Mithra signs Exclusive agreement for Tibelia® in Canada Tibelia® would be the first tibolone-based Hormone Therapy product available in Canada Marketing authorization process is ongoing Tibelia® already [...]
Refixia® (nonacog beta pegol; N9-GP) approved in the EU
06/06/2017
Company Announcement No 42/2017 This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients. The issuer of this announcement warrants that they are solely [...]

Pages